

G Vignir Helgason

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7954727/g-vignir-helgason-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,710
citations

17
h-index

31
g-index

31
ext. papers

2,084
ext. citations

9.6
avg. IF

4.72
L-index

#	Paper	IF	Citations
30	Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1109-23	15.9	439
29	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. <i>Blood</i> , 2012 , 119, 1501-10	2.2	301
28	Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. <i>Nature Medicine</i> , 2017 , 23, 1234-1240	50.5	247
27	Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. <i>Blood</i> , 2011 , 118, 2035-43	2.2	93
26	The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. <i>Nature Reviews Cancer</i> , 2020 , 20, 158-173	31.3	74
25	The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. <i>Stem Cells</i> , 2014 , 32, 2324-37	5.8	71
24	ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. <i>Autophagy</i> , 2016 , 12, 936-48	10.2	65
23	Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. <i>Leukemia</i> , 2019 , 33, 981-994	10.7	63
22	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 467-478	9.7	51
21	Autophagy in blood cancers: biological role and therapeutic implications. <i>Haematologica</i> , 2013 , 98, 1335-48	4.8	42
20	Do we need more drugs for chronic myeloid leukemia?. <i>Immunological Reviews</i> , 2015 , 263, 106-23	11.3	34
19	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 2289-2300	12.9	30
18	Role of autophagy in cancer prevention, development and therapy. <i>Essays in Biochemistry</i> , 2013 , 55, 133-56	5.6	30
17	-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. <i>Blood</i> , 2018 , 131, 1532-1544	15.4	28
16	Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. <i>Current Cancer Drug Targets</i> , 2013 , 13, 724-34	2.8	26
15	Targeting chronic myeloid leukemia stem cells. <i>Current Hematologic Malignancy Reports</i> , 2010 , 5, 81-7	4.4	26
14	Utilizing Stimulated Raman Scattering Microscopy To Study Intracellular Distribution of Label-Free Ponatinib in Live Cells. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 2028-2034	8.3	21

13	Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 381-92	3.5	15
12	The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought. <i>Frontiers in Cell and Developmental Biology</i> , 2018 , 6, 120	5.7	12
11	Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. <i>Cancer Research</i> , 2010 , 70, 4074-80	10.1	9
10	Autophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemia. <i>FEBS Journal</i> , 2019 , 286, 1271-1283	5.7	9
9	Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. <i>Leukemia</i> , 2021 ,	10.7	7
8	BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020 , 34, 640-644	10.7	6
7	Folate metabolism: a re-emerging therapeutic target in haematological cancers. <i>Leukemia</i> , 2021 , 35, 1539-1551	10.7	4
6	Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. <i>Experimental Hematology</i> , 2009 , 37, 206-14	3.1	2
5	Therapy Resistant CML Stem Cells Are Dependent on Mitochondrial Oxidative Metabolism for Their Survival. <i>Blood</i> , 2016 , 128, 932-932	2.2	2
4	ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy. <i>Science Translational Medicine</i> , 2021 , 13, eabd5016	17.5	2
3	Auto-Commentary on: "Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells". <i>Molecular and Cellular Oncology</i> , 2018 , 5, e1403532	1.3	1
2	Autophagy in hematopoiesis and leukemogenesis 2022 , 125-141		0
1	Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia.. <i>Autophagy</i> , 2022 , 1-3	10.2	0